Welcome to our dedicated page for Roger news (Ticker: ROG), a resource for investors and traders seeking the latest updates and insights on Roger stock.
Rogers Corporation (ROG) delivers engineered materials and advanced electronics solutions powering global industries from clean energy to automotive systems. This news hub provides investors and professionals with authoritative updates on corporate developments shaping the industrial technology sector.
Access real-time press releases, financial announcements, and strategic partnership details in one curated location. Track ROG's innovations in circuit materials, elastomer components, and mission-critical industrial solutions through verified updates directly from the company and trusted sources.
Key updates include earnings reports, product launches, leadership changes, and market expansion initiatives. Discover how ROG's focus on reliability and global manufacturing expertise addresses evolving demands in communications infrastructure and industrial applications.
Bookmark this page for streamlined access to Rogers Corporation's latest milestones and operational updates. Combine strategic insights with timely news to inform your analysis of this materials technology leader.
Roche (ROG) announced on October 13, 2025 that the FDA cleared its Elecsys pTau181 blood test as the only blood-based biomarker test indicated for use in primary care to help rule out Alzheimer's-related amyloid pathology. The test is for patients aged 55 and older, was developed with Eli Lilly, and showed a 97.9% negative predictive value in a multicenter study of 312 participants reflective of a primary-care population. With > 4,500 Roche instruments already in U.S. labs and recent CE Mark/IVDR certification, Roche says the test can broaden access, improve referrals, and reduce more invasive confirmatory testing such as PET and CSF.
Rogers Corporation (NYSE:ROG) reported Q2 2025 financial results with net sales of $202.8 million, up 6.5% sequentially. The company posted a net loss of $73.6 million, primarily due to $71.8 million in non-cash impairment charges and $4.3 million in restructuring expenses. Gross margin improved to 31.6%, up 170 basis points from Q1.
Key highlights include adjusted earnings per share of $0.34, a 25.9% sequential increase, and $28 million in share repurchases. The company announced cost reduction initiatives in its AES curamik® business, expected to save over $13 million annually. For Q3 2025, Rogers projects net sales between $200-215 million and adjusted earnings per share of $0.50-0.90.
Rogers Corporation (NYSE:ROG) announced a significant leadership transition as CEO Colin Gouveia has departed, with Ali El-Haj stepping in as interim President and CEO. The Board has initiated a comprehensive search for a permanent CEO, considering both internal and external candidates.
El-Haj brings over 30 years of international experience in automotive and manufacturing industries, most recently leading Techniplas through acquisitions and COVID-19 challenges. His background includes successful leadership roles at CAP-CON Automotive Technologies and Casco Products, along with advanced degrees in physics and engineering.
Rogers Corporation (ROG) reported Q1 2025 financial results with net sales of $190.5 million, showing a slight decrease of 0.9% from the previous quarter. The company posted a net loss of $1.4 million, or $(0.08) per diluted share.
Key highlights:
- Advanced Electronics Solutions sales increased 1.8%, driven by higher ADAS and aerospace/defense sales
- Elastomeric Material Solutions sales decreased 4.3% due to lower portable electronics demand
- Cash position strengthened to $175.6 million
- Gross margin at 29.9%, down from 32.1% in Q4 2024
Looking ahead, Rogers projects Q2 2025 net sales between $190-205 million with gross margins of 31-33%. The company has implemented measures to offset tariff impacts and reduce operating expenses. CEO Colin Gouveia noted limited visibility for the remainder of the year due to global trade uncertainties but emphasized focus on commercial, innovation, and operational priorities.
Rogers (NYSE:ROG) has announced it will release its first quarter 2025 financial results on April 29, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.
The earnings call will be led by Colin Gouveia, President and CEO, alongside Laura Russell, Senior Vice President and CFO. Investors can access the live webcast and accompanying slide presentation through Rogers' Investor Relations website at rogerscorp.com/investors, where a replay will also be available.
Rogers is a global leader in engineered materials, specializing in solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, wireless infrastructure, and energy-efficient motor drives.
Rogers (NYSE:ROG) reported Q4 2024 financial results with net sales of $192.2 million, representing an 8.6% decrease from the previous quarter. The decline was attributed to lower sales in both AES and EMS business units, particularly in wireless infrastructure and industrial sectors.
Gross margin decreased to 32.1% from 35.2% in the prior quarter due to lower volume and unfavorable product mix. GAAP operating margin fell to -2.6% from 6.9%, while adjusted operating margin decreased by 700 basis points to 4.7%. The company reported GAAP earnings per diluted share of $(0.03) compared to $0.58 in the previous quarter, and adjusted earnings of $0.46 per diluted share versus $0.98.
The company ended the quarter with $159.8 million in cash and cash equivalents, an increase of $13.4 million. Net cash provided by operating activities was $33.7 million, with capital expenditures of $15.4 million.
Rogers (NYSE:ROG) has announced it will release its fourth quarter and full year 2024 financial results on February 19, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.
The earnings call will be led by Colin Gouveia, President and CEO, alongside Laura Russell, Senior VP and CFO. Investors can access the live webcast and related presentation materials through Rogers' Investor Relations website, where a replay will also be available.
Rogers is a global leader in engineered materials, specializing in solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, wireless infrastructure, and industrial equipment.
Roche (RHHBY) has received FDA 510(k) clearance for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail, a groundbreaking test for diagnosing B-cell lymphoma. This follows its CE Mark approval in June 2024. The test is the first clinically approved in-situ hybridisation (ISH) test capable of assessing all B-cell lymphoma subtypes.
The highly-sensitive test helps distinguish between B-cell cancer and normal immune responses, enabling faster diagnosis and treatment initiation. It can evaluate over 60 B-cell lymphoma subtypes and plasma cell neoplasms on a single tissue slide, working with small biopsies and formalin-fixed tissue. This reduces the need for fresh tissue samples and additional biopsies.
B-cell lymphoma represents about 85% of non-Hodgkin lymphoma (NHL) cases, with NHL being one of the most common cancers in the US, accounting for 4% of all cancer cases and causing over 80,000 deaths annually.
Rogers (NYSE: ROG) has announced the appointment of Woon Keat Moh as an independent member of its Board of Directors, effective January 1, 2025. This addition will expand the Board to nine members, with eight being independent directors. Moh brings nearly 30 years of experience in the specialty materials industry, including significant leadership roles in both Asia and North America. Board Chair Peter Wallace emphasized that Moh's extensive experience in leading global businesses will contribute to Rogers' strategy and shareholder value creation.